Screening for Hydroxychloroquine Retinal Toxicity in Indian Patients. 2021

Nikunjkumar V Dadhaniya, and Isha Sood, and Abhishek Patil, and Uma Mallaiah, and Sundeep Upadhyaya, and Rohini Handa, and Sirinder J Gupta
From the Departments of Rheumatology.

OBJECTIVE Several studies have reported hydroxychloroquine (HCQ) retinal toxicity in East Asian patients. However, at present, there are limited data from Indian patients. The aim of this study was to investigate the prevalence and pattern of HCQ retinal toxicity in Indian population and to see if screening protocol for retinal toxicity in Indian patients should be any different to others. METHODS This was a cross-sectional study involving adult patients with autoimmune rheumatic diseases who had received HCQ for at least 5 years or a cumulative dose of at least 500 g. Retinal toxicity was evaluated using fundus examination, visual fields 10-2 and 30-2 protocol, and spectral domain optical coherence tomography. RESULTS Of 110 patients screened, retinal toxicity was found in 7 patients (6.36%). A parafoveal pattern was found in 4 patients, whereas a mixed parafoveal and perifoveal pattern was found in 3 patients. None of the patients had isolated perifoveal pattern. Except for the one patient, all the patients with retinal toxicity had more than 10 years (mean, 13 ± 4.89 years; range, 5-20 years) of HCQ usage with a mean cumulative dose of 1573.7 ± 771.5 g. The mean daily dose was 5 ± 1.6 mg/kg per day. CONCLUSIONS Hydroxychloroquine retinal toxicity is more common than previously recognized in patients who have used the drug for more than 5 years. The toxicity manifests as a parafoveal or a mixed parafoveal and perifoveal pattern in Indian patients.

UI MeSH Term Description Entries
D012164 Retinal Diseases Diseases involving the RETINA. Disease, Retinal,Diseases, Retinal,Retinal Disease
D003430 Cross-Sectional Studies Studies in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with LONGITUDINAL STUDIES which are followed over a period of time. Disease Frequency Surveys,Prevalence Studies,Analysis, Cross-Sectional,Cross Sectional Analysis,Cross-Sectional Survey,Surveys, Disease Frequency,Analyses, Cross Sectional,Analyses, Cross-Sectional,Analysis, Cross Sectional,Cross Sectional Analyses,Cross Sectional Studies,Cross Sectional Survey,Cross-Sectional Analyses,Cross-Sectional Analysis,Cross-Sectional Study,Cross-Sectional Surveys,Disease Frequency Survey,Prevalence Study,Studies, Cross-Sectional,Studies, Prevalence,Study, Cross-Sectional,Study, Prevalence,Survey, Cross-Sectional,Survey, Disease Frequency,Surveys, Cross-Sectional
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006886 Hydroxychloroquine A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970) Hydroxychlorochin,Oxychlorochin,Oxychloroquine,Hydroxychloroquine Sulfate,Hydroxychloroquine Sulfate (1:1) Salt,Plaquenil
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D018501 Antirheumatic Agents Drugs that are used to treat RHEUMATOID ARTHRITIS. Anti-Rheumatic Agent,Anti-Rheumatic Drug,Antirheumatic Agent,Antirheumatic Disease-Modifying Second-Line Drug,Antirheumatic Drug,DMARD,Disease-Modifying Antirheumatic Drug,Disease-Modifying Antirheumatic Drugs,Anti-Rheumatic Agents,Anti-Rheumatic Agents, Non-Steroidal,Anti-Rheumatic Drugs,Antirheumatic Disease-Modifying Second-Line Drugs,Antirheumatic Drugs,Antirheumatic Drugs, Disease-Modifying,Disease-Modifying, Antirheumatic Second-Line Drugs,Agent, Anti-Rheumatic,Agent, Antirheumatic,Anti Rheumatic Agent,Anti Rheumatic Agents,Anti Rheumatic Agents, Non Steroidal,Anti Rheumatic Drug,Anti Rheumatic Drugs,Antirheumatic Disease Modifying Second Line Drug,Antirheumatic Disease Modifying Second Line Drugs,Antirheumatic Drug, Disease-Modifying,Antirheumatic Drugs, Disease Modifying,Disease Modifying Antirheumatic Drug,Disease Modifying Antirheumatic Drugs,Disease Modifying, Antirheumatic Second Line Drugs,Drug, Anti-Rheumatic,Drug, Antirheumatic,Drug, Disease-Modifying Antirheumatic,Non-Steroidal Anti-Rheumatic Agents
D041623 Tomography, Optical Coherence An imaging method using LASERS that is used for mapping subsurface structure. When a reflective site in the sample is at the same optical path length (coherence) as the reference mirror, the detector observes interference fringes. OCT Tomography,Optical Coherence Tomography,Coherence Tomography, Optical,Tomography, OCT

Related Publications

Nikunjkumar V Dadhaniya, and Isha Sood, and Abhishek Patil, and Uma Mallaiah, and Sundeep Upadhyaya, and Rohini Handa, and Sirinder J Gupta
January 1990, Eye (London, England),
Nikunjkumar V Dadhaniya, and Isha Sood, and Abhishek Patil, and Uma Mallaiah, and Sundeep Upadhyaya, and Rohini Handa, and Sirinder J Gupta
January 2012, Ophthalmology,
Nikunjkumar V Dadhaniya, and Isha Sood, and Abhishek Patil, and Uma Mallaiah, and Sundeep Upadhyaya, and Rohini Handa, and Sirinder J Gupta
November 2007, Archives of ophthalmology (Chicago, Ill. : 1960),
Nikunjkumar V Dadhaniya, and Isha Sood, and Abhishek Patil, and Uma Mallaiah, and Sundeep Upadhyaya, and Rohini Handa, and Sirinder J Gupta
April 2019, The New England journal of medicine,
Nikunjkumar V Dadhaniya, and Isha Sood, and Abhishek Patil, and Uma Mallaiah, and Sundeep Upadhyaya, and Rohini Handa, and Sirinder J Gupta
January 2019, Rheumatology (Oxford, England),
Nikunjkumar V Dadhaniya, and Isha Sood, and Abhishek Patil, and Uma Mallaiah, and Sundeep Upadhyaya, and Rohini Handa, and Sirinder J Gupta
April 2016, Klinische Monatsblatter fur Augenheilkunde,
Nikunjkumar V Dadhaniya, and Isha Sood, and Abhishek Patil, and Uma Mallaiah, and Sundeep Upadhyaya, and Rohini Handa, and Sirinder J Gupta
June 2016, Rheumatology (Oxford, England),
Nikunjkumar V Dadhaniya, and Isha Sood, and Abhishek Patil, and Uma Mallaiah, and Sundeep Upadhyaya, and Rohini Handa, and Sirinder J Gupta
April 2020, The Journal of rheumatology,
Nikunjkumar V Dadhaniya, and Isha Sood, and Abhishek Patil, and Uma Mallaiah, and Sundeep Upadhyaya, and Rohini Handa, and Sirinder J Gupta
January 2023, Frontiers in pharmacology,
Nikunjkumar V Dadhaniya, and Isha Sood, and Abhishek Patil, and Uma Mallaiah, and Sundeep Upadhyaya, and Rohini Handa, and Sirinder J Gupta
October 2013, Cutaneous and ocular toxicology,
Copied contents to your clipboard!